( dmeasurable VEGF ZFP TF and increased ...)Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting,Health

d measurable VEGF ZFP TF and increased levels of all of the major isoforms of the VEGF protein. They observed a corresponding neuroprotective effect with a statistically significant decrease in nerve fiber degradation and post-injury nerve cell death. They also noted an increase in blood vessel density around the injury. Most importantly, in a severe model of SCI where animals are paraplegic post- injury, they observed a statistically significant (p<0.0001) improvement of hind-limb function over time.

"I am very impressed by the improvements that we were able to generate through treatment of acutely injured spinal cord with the VEGF ZFP TF," stated Dr. Fehlings. "In earlier studies we had observed clear increases in VEGF protein levels and good evidence of a neuroprotective effect of the ZFP TF. In these more recent experiments we have seen evidence of improved functional outcomes that are quite impressive compared with any other therapeutic approach that we have evaluated including stem cell therapies. We look forward to continuing these studies in collaboration with Sangamo and believe that this VEGF-activating ZFP TF may hold promise as a unique therapy for spinal cord injury and other forms of neural injury."

"Dr. Fehling's studies, particularly the experiments that demonstrate an improvement in hind-limb function, are very encouraging," said Dale Ando, M.D. Sangamo's vice president of therapeutic development and chief medical officer. "The outcomes of these studies are consistent with other data from a variety of models that suggest that our ZFP TF activator of VEGF expression has regenerative effects on nerves and a positive effect on the health of nerves injured by both mechanical means such as in spinal cord injury and the toxicity that is a function of diabetes. We are very pleased to continue to work with Dr Fehlings who is world-renown for his work on SCI and has significant clinical trial experience in this area."

S. Kaye Spratt, Ph.
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis